Tryptamine: A possible endogenous substrate for CYP2D6

Pharmacogenetics

Volumn 7, Issue 2, 1997, Pages 85-93

  Martínez, Carmen ^a   Agúndez, José A G ^a   Gervasini, Guillermo ^a   Martín, Ramón ^a   Benítez, Julio ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

CYP2D6; Metabolism; Tryptamine

Indexed keywords

CYTOCHROME P450; DEXTROMETHORPHAN; QUINIDINE; TRYPTAMINE;

ARTICLE; COMPETITIVE INHIBITION; DRUG EFFECT; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; NEUROTRANSMITTER RELEASE; PARKINSON DISEASE; PRIORITY JOURNAL;

CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; DOSE-RESPONSE RELATIONSHIP, DRUG; HOMOZYGOTE; HUMANS; MICROSOMES, LIVER; NEUROTRANSMITTER AGENTS; TRYPTAMINES;

EID: 0030951095     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199704000-00001     Document Type: Article

References (72)

1. Agúndez JAG, Martínez C, Ladero JM, Ledesma MC, Ramos JM, Martín R, Rodriguez A, Jara C, Benítez J. Debrisoquine oxidation genotype and susceptibility to lung cancer. Clin Pharmacol Ther 1994: 55, 10-14.
2. Agúndez JAG, Jiménez-Jiḿnez FJ, Luengo A, Bernal ML, Molina JA, Ayuso L, Vazquez A, Parra J, Duarte J, Coria F, Ladero JM, Alvarez CJ, Benítez J. Association between the oxidative polymorphism and the early onset of Parkinson's disease. Clin Pharmacol Ther 1995: 57, 291-298.
3. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992: 339, 1017-1018.
4. Ayesh RA, Idle JR, Ritchie JC, Crothers MJ, Hezel MR. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 1984: 312, 196-170.
5. Barbeau A, Cloutier T, Roy M, Plasse L, Paris S, Poirier J. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet 1985: 11, 1213-1215.
6. Barnhart JW. The urinary excretion of dextromethorphan and three metabolites in dogs and humans. Toxicol Appl Pharmacol 1980: 55, 43-48.
7. Baron BM, Ogden A, Seigel BW. Rapid down regulation of β-adrenoceptors by co-administration of desipramine and fluoxetine. Eur J Pharmacol 1988: 154, 125-134.
8. Bertilsson L, Alm C, de las Carreras C, Widen J, Edman G, Schalling D. Debrisoquine hydroxylation polymorphism and personality. Lancet 1989: V, 555.
9. Boobis AR, Murray S, Kahn CG, Robertz GM, Davies DS. Substrate specificity of the form of cytochrome P-450 catalysing the 4-hydroxylation of debrisoquin in man. Mol Pharmacol 1983: 23, 474-481.
10. Bouchardy C, Benhamou S, Dayer P. The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res 1996: 56, 251-253.
11. Boulton AA, Marjerrison GL. Effect of L-DOPA therapy on urinary p-tyramine excretion and EEG changes in Parkinson's disease. Nature 1972: 236, 76-78.
12. Broly F, Libersa C, L'Hermitte M, Becthel P, Dupuis B. Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. Br J Clin Pharmacol 1989: 28, 29-36.
13. Brune GG, Plughaupt KW. Effects of L-DOPA treatments on indole metabolism in Parkinson's disease. Experientia 1971: 27, 516.
14. Brune GG, Himwhich HE. Indole metabolites in schizophrenic patients. Arch Gen Psychiat 1962: 6, 324-328.
15. Calne DB, Langjston JW. Etiology of Parkinson's disease. Lancet 1983: II, 1457-1459.
16. Caporaso N, DeBaun MR, Rothman N. Lung cancer and CYP2D6 (the debrisoquine polymorphism): sources of heterogeneity in the proposed association. Pharmacogenetics 1995: 5, S129-S134.
17. Chen ZR, Somogyi AA, Bochner F. Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man. Ther Drug Monit 1990: 12, 97-104.
18. Cholerton S, Daly AK, Idle JR. The role of individual human cytochromes P-450 in drug metabolism and clinical aspects. Trends Pharmacol Sci 1992: 13, 434-439.
19. Dabadie H, Mons N, Geffard M. Simultaneous detection of tryptamine and dopamine in rat substantia nigra and raphe nuclei using specific antibodies. Brain Res 1990: 512, 138-142.
20. Dabadie H, Geffard M, Charrier MC, Locuratolo D, Berrier C, Jacquesy JC. First characterization of 6-hydroxytryptamine in the rat midbrain using specific antibodies. J Neurochem 1992: 58, 1292-1299.
21. De Vane CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatr 1994: 55 suppl. 38-45.
22. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism-clinical aspects. Pharmacol Ther 1990: 46, 377-394.
23. Fischer V, Vickers AEM, Heitz F, Mahadevan S, Baldeck JP, Minery P, Tynes R. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondasetron. Drug Metab Disp 1994: 22, 269-274.
24. Fonne-Pfister R, Bargetzi MJA, Meyer UA, MPTP the neurotoxin inducing Parkinson's disease, is a potent inhibitor of human and rat P-450 enzymes (P-450bufl. P-450db1) catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun 1987: 148, 1144-1150.
25. Fonne-Pfister R, Meyer UA. Xenobiotic and endobiotic inhibitors of cytochrome P-450db1 function, the target of the debrisoquine/ sparteine type polymorphism. Biochem Pharmacol 1988: 37, 3829-3835.
26. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Human Genet 1991: 48, 943-950.
27. García-Agúndez JA, Luengo A, Benítez J, Aminopyrine-N-demethylase activity in human liver microsomes. Clin Pharmacol Ther 1990: 45, 490-495.
28. Guengerich FP. Characterization of the roles of human cytochrome P-450 enzymes in carcinogen metabolism. Asia Pacific J Pharmacol 1990: 3, 363-371.
29. Heim M, Meyer UA. Genetic polymorphism of debrisoquine oxidation: Analysis of mutant alleles of CYP2D6 by restriction fragment analysis and by allele specific amplification. Methods Enzymol 1991: 206, 173-183.
30. Herkert EE, Keup W. Excretion patterns of tryptamine, indoleacetic acid and 5-hydroxyindoleacetic acid, and their correlation with mental changes in schizophrenic patients under medication with alphamethyldopa. Psychopharmacol (Berl) 1969: 15, 48-49.
31. Idle JR. Hydroxylation phenoptype and hepatocellular carcinoma. In: Davis M, Tredger JM, Williams R, eds. Drug reactions and the liver. London: Pitman Medical, 1981: 313-315.
32. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 1993: 3, 197-204.
33. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Nati Acad Sci USA 1993: 90, 11825-11829.
34. Jones RSG. Tryptamine: a neuromodulator or neurotransmitter in mammalian brain? Prog Neurobiol 1982: 19, 117-139.
35. Juorio AV, Paterson IA. Tryptamine may couple dopaminergic and serotoninergic transmission in brain. Gen Pharmacol 1990: 21, 613-616.
36. Juorio AV. The effects of some antipsychotic drugs, D-amphetamine and reserpine in the concentration and rate of accumulation of tryptamine and 5-hydroxytryptamine in the mouse striatum. Can J Physiol Pharmac. 1982: 60, 376-380.
37. Kalow W, Tyndale RF. Debrisoquine/sparteine monooxygenase and other P-450s in brain. In: W Kalow, ed. Pharmacogenetics of drug metabolism. New York: Pergamon Press Inc. 1992: 791-795.
38. Kerry NL, Somogyi AA, Bochner F, Mikus G. The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes. Br J Clin Pharmacol 1994: 38, 243-248.
39. Kobayashi S, Murray S, Watson D, Sesardic D, Davies DS, Boobis AR. The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rats is inverse of that in man. Biochem Pharmacol 1989: 38, 2795-2799.
40. Koymans L, Vermeulen NPE, Van Acker SABE, Tecopele JM, Heykaants JJP, Lavrijsen K, Meuldermans W, Kelder GMDO. A predictive model for substrates of cytochrome P-450-debrisoquine (2D6). Chem Res Toxicol 1992: 5, 211-219.
41. Keuhl FA, Vanden-Heuval WJA, Ormond RE. Urinary metabolites in Parkinson's disease. Nature 1968: 217, 471-490.
42. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219, 979-980.
43. Llerena A, Cobaleda J, Benítez J. Debrisoquine hydroxylation phenotypes in healthy volunteers [Letter]. Lancet 1989: 1389.
44. Lowry OH, Rosebrough NJ, Farr AL, Randall FJ. Protein measurement with Folin phenol reagent. J Biol Chem 1951: 6, 315-323.
45. Meyer UA, Gut J, Kronback T, Skoda C, Meyer UT, Catin T, Dayer P. The molecular mechanisms of two common polymorphisms of drug oxidation- evidence for functional changes in cytochromo P-450 isozymes catalising bufuralol and mephenytoin oxidation. Xenobiotica 1986: 31, 69-72.
46. Mills MH, Finlay DC, Haddad PR. Determination of melatonin and monoamines in rat pineal using reversed-phase ion-interaction chromatography with fluorescence detection. J Chromatogr 1991: 564, 93-102.
47. Mousseau DD. Tryptamine: a metabolite of tryptophan implicated in various neuropsychiatric disorders. Metabol Brain Dis 1993: 8, 1-44.
48. Neff NH, Yang HYT. Another look at the monoamine oxidase and the monoamine oxidase inhibitor drugs. Life Sci 1974: 14, 2061-2074.
49. Neitzel HA. A routine method for the establishment of permanent growing lymphoblastoid cell lines. Hum Genet 1986: 73, 320-332.
50. Otton SV, Crewe HK, Lennard MS, Tucker GT, Woods HF. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P-450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther 1988: 247, 242-247.
51. Otton S, Dafang W, Russell T, Joffe MD, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993: 53, 401-409.
52. Pelkonen O, Breimer DD. Role of environmental factors in the pharmacokinetics of drugs: Considerations with respect to animal models. P-450 enzymes, and probe drugs. In: Weilling PG, Balant LP, eds. Handbook of experimental pharmacology, vol 110. Pharmacokinetics of drugs. Berlin: Springer Verlag, 1994: 43-56.
53. Pfaff G, Briegel P, Lamprecht I. Inter-individual variation in the metabolism of dextromethorphan. Int J Pharmacol 1983: 14, 173-189.
54. Rosenbaum JF. Managing selective serotonin reuptake inhibitor-drug interactions in clinical practice. Clin Pharmacokinet 1995: 29 suppl. 53-59.
55. Ryan DE, Levin W. Purification and characterization of hepatic microsomal cytochrome P-450. In: Kalow W, ed. Pharmacogenetics of drug metabolism. New York: Pergamon Press Inc. 1992: 453-526.
56. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA. Two mutant alleles of the human cytochrome P450db1 gene (P450IID1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 1988: 85, 5240-5243.
57. Smith I, Kellow AH. Aromatic amines and Parkinson's disease. Nature 1969: 221, 1261.
58. Smith CAD, Gough AC, Leigh PN, Summers BA, Harding AE, Maranganore DM, Sturman SG, Schapira AHV, Willian AC, Spurr NK, Wolf CR. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992: 339, 1375-1377.
59. Speirs CJ, Murray S, Boobis DS, Seddon CE, Davies DS. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Br J Clin Pharmacol 1986: 22, 739-743.
60. Turner WJ, Merlis S. Effect of some indolealkylamines on man. Arch Neurol Psychiat 1959: 81, 121-129.
61. Tyndale RE, Sunahara R, Inaba T, Kalow W, Gonzalez FJ, Niznik HB. Neuronal cytochrome P-450 IID1 (debrisoquine/sparteine type): Potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P-450 gene CYP2D6. Mol Pharmacol 1991a: 40, 63-68.
62. Tyndale R, Aoyama T, Broly F, Matsunaga T, Inaba T, Kalow W, Gelboin HV, Meyer UA, Gonzalez FJ. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics 1991b: 1, 26-32.
63. Volicer L, Crino PB. Involvement of free radicals in dementia of the Alzheimer Type: a hypothesis. Neurobiol Aging 1990: 11, 567-571.
64. Weyler W, Hsu YPP, Breakefield X. Biochemistry and genetics of monoamine oxidase. In: Kalow W, ed. Pharmacogenetics of drug metabolism. New York: Pergamon Press Inc. 1992: 333-356.
65. Wiltfang J, Thiele G, Weissenborn K, Huther G, Reimer A, Pogeler B, Kanzler H, Schmidt FW, Wiltfang A. Early hepatic encephalopathy, neurophysiological assessment and correlation with biochemical parameters. In: Bengtsson F, Jeppon B, Almdal T, Vilstrup H, eds. Hepatic encephalopathy and metabolic nitrogen exchange. CRC Press: Boston, 1991, 49-58.
66. Wolf CR, Smith CAD, Gough AC, Moss JE, Vallis KA, Howard G, Carey FJ, Mills K, McNee W, Carmichael J, Spurr NK. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis 1992: 13, 1035-1038.
67. Wolff T, Dislerath LM, Worthington MT, Groopman JD, Hammons GJ, Kadlubar FF, Prough RA, Martin MV, Guengerich FP. Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. Cancer Res 1985: 45, 2116-2222.
68. Wolff T, Dislerath LM, Worthington MT, Guengerich FP. Human liver debrisoquine 4-hydroxylase: test for specificity toward various monooxigenase substrates and model of the active site. Arch Toxicol 1987: 60, 89-90.
69. Wong KS, Goyal RN, Wrona MZ, Blank CL, Dryhurst G. 7-S-glutathionyl-tryptamine-4,5-dione: a possible aberrant metabolite of serotonin. Biochem Pharmacol 1993: 46, 1637-1652.
70. Young SN, Anderson GM, Gauthier S, Purdy WC. The origin of indoleacetic acid and indolepropionic acid in rat and human cerebrospinal fluid. J Neurochem 1980: 34, 1087-1092.
71. Young SN, Lal S. CNS tryptamine metabolism in hepatic coma. J Neural Transm 1980:47, 153-161.
72. Zhang Y, Britto MR, Valderhaug KL, Wedlund PJ, Smith RA. Dextromethorphan: Enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. Clin Pharmacol Ther 1992: 51, 647-655.